163 related articles for article (PubMed ID: 15975279)
1. [Detection and comparison of transcriptional activities of tumor-specific survivin and alpha-fetoprotein promoters in human hepatocellular carcinoma cells].
Kuang G; Huang AL; Tang N
Zhonghua Gan Zang Bing Za Zhi; 2005 Jun; 13(6):440-2. PubMed ID: 15975279
[TBL] [Abstract][Full Text] [Related]
2. Regulatory regions of growth-related genes can activate an exogenous gene of the alpha-fetoprotein promoter to a comparable degree in human hepatocellular carcinoma cells.
Tomizawa M; Saisho H; Tagawa M
Anticancer Res; 2003; 23(4):3273-7. PubMed ID: 12926063
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of improved α-fetoprotein promoter-mediated tBid delivered by folate-PEI600-cyclodextrin nanopolymer vector in hepatocellular carcinoma.
Hu BG; Liu LP; Chen GG; Ye CG; Leung KK; Ho RL; Lin MC; Lai PB
Exp Cell Res; 2014 Jun; 324(2):183-91. PubMed ID: 24726886
[TBL] [Abstract][Full Text] [Related]
4. [Effects of human telomerase reverse transcriptase promoter and survivin promoter in targeted tumor gene therapy].
Zhang Y; Ma H; Liu SL; Liu YX; Zheng DX
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(7):475-9. PubMed ID: 18642790
[TBL] [Abstract][Full Text] [Related]
5. A promoter region of the midkine gene that is frequently expressed in human hepatocellular carcinoma can activate a suicide gene as effectively as the alpha-fetoprotein promoter.
Tomizawa M; Yu L; Wada A; Tamaoki T; Kadomatsu K; Muramatsu T; Matsubara S; Watanabe K; Ebara M; Saisho H; Sakiyama S; Tagawa M
Br J Cancer; 2003 Sep; 89(6):1086-90. PubMed ID: 12966430
[TBL] [Abstract][Full Text] [Related]
6. [Detection of transcriptional activities of tumor-specific survivin promoter in human prostatic carcinoma].
Luo XM; Liu JY; Su MQ; Hao XK
Zhonghua Nan Ke Xue; 2007 Jun; 13(6):502-6. PubMed ID: 17615972
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy.
Ulasov IV; Rivera AA; Sonabend AM; Rivera LB; Wang M; Zhu ZB; Lesniak MS
Cancer Biol Ther; 2007 May; 6(5):679-85. PubMed ID: 17404502
[TBL] [Abstract][Full Text] [Related]
8. [Gene therapy using a dominant negative form of the protein phosphatase 2A catalytic subunit a driven by a hepatoma tissue-specific promoter achieves effective growth inhibition of hepatoma cells].
Li DM; Li W; Tao M; Chen K; Gong FR; Xu ZK; Chen Z
Zhonghua Gan Zang Bing Za Zhi; 2013 Jun; 21(6):459-63. PubMed ID: 24034849
[TBL] [Abstract][Full Text] [Related]
9. Correlation between the levels of survivin and survivin promoter-driven gene expression in cancer and non-cancer cells.
Konopka K; Spain C; Yen A; Overlid N; Gebremedhin S; Düzgüneş N
Cell Mol Biol Lett; 2009; 14(1):70-89. PubMed ID: 18839071
[TBL] [Abstract][Full Text] [Related]
10. An advanced strategy of enhanced specific gene expression for hepatocellular carcinoma.
Takikawa H; Mafune K; Hamada H; Nettelbeck DM; Müller R; Makuuchi M; Kaminishi M
Int J Oncol; 2003 May; 22(5):1051-6. PubMed ID: 12684671
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of tumor-specific promoter activities in melanoma.
Lu B; Makhija SK; Nettelbeck DM; Rivera AA; Wang M; Komarova S; Zhou F; Yamamoto M; Haisma HJ; Alvarez RD; Curiel DT; Zhu ZB
Gene Ther; 2005 Feb; 12(4):330-8. PubMed ID: 15696177
[TBL] [Abstract][Full Text] [Related]
12. α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy.
Peng YF; Shi YH; Ding ZB; Zhou J; Qiu SJ; Hui B; Gu CY; Yang H; Liu WR; Fan J
PLoS One; 2013; 8(2):e53072. PubMed ID: 23468839
[TBL] [Abstract][Full Text] [Related]
13. [Construction of a hepatoma-targeting vector of adeno-associated virus containing human alpha-fetoprotein promoter and wild p53 gene in gene therapy of liver cancer].
Cheng J; Leng X; Peng J
Zhonghua Yi Xue Za Zhi; 2000 Jun; 80(6):461-3. PubMed ID: 11798803
[TBL] [Abstract][Full Text] [Related]
14. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.
Van Houdt WJ; Haviv YS; Lu B; Wang M; Rivera AA; Ulasov IV; Lamfers ML; Rein D; Lesniak MS; Siegal GP; Dirven CM; Curiel DT; Zhu ZB
J Neurosurg; 2006 Apr; 104(4):583-92. PubMed ID: 16619663
[TBL] [Abstract][Full Text] [Related]
15. The targeted expression of interleukin-2 in human hepatocellular carcinoma cells.
He P; Tang ZY; Ye SL; Liu BB; Liu YK
J Exp Clin Cancer Res; 2000 Jun; 19(2):183-7. PubMed ID: 10965816
[TBL] [Abstract][Full Text] [Related]
16. Targeting gene therapy for hepatocarcinoma cells with the E. coli purine nucleoside phosphorylase suicide gene system directed by a chimeric alpha-fetoprotein promoter.
Cai X; Zhou J; Chang Y; Sun X; Li P; Lin J
Cancer Lett; 2008 Jun; 264(1):71-82. PubMed ID: 18407409
[TBL] [Abstract][Full Text] [Related]
17. [Construction and application of a noval gene-target therapy system in hepatocellular carcinoma].
Zhang G; Liu T; Wang Z
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Jun; 29(3):563-7, 592. PubMed ID: 22826959
[TBL] [Abstract][Full Text] [Related]
18. Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma.
Pin RH; Reinblatt M; Fong Y
Ann Surg; 2004 Oct; 240(4):659-65; discussion 665-6. PubMed ID: 15383793
[TBL] [Abstract][Full Text] [Related]
19. Cell-specific expression of artificial microRNAs targeting essential genes exhibit potent antitumor effect on hepatocellular carcinoma cells.
Mao C; Liu H; Chen P; Ye J; Teng L; Jia Z; Cao J
Oncotarget; 2015 Mar; 6(8):5707-19. PubMed ID: 25691059
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter.
Ido A; Uto H; Moriuchi A; Nagata K; Onaga Y; Onaga M; Hori T; Hirono S; Hayashi K; Tamaoki T; Tsubouchi H
Cancer Res; 2001 Apr; 61(7):3016-21. PubMed ID: 11306481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
